Comparison of Arginine and Citrulline

Comparison of the effects of Arginine and Citrulline supplementation on the prognosis of critically ill patinents in intensive care unit receiving enteral nutrition

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201108027199N1

Enrollment

105

Registered

2011-10-28

Start date

2011-09-29

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

head trauma patients. Intracranial injury

Interventions

Intervention 1: Arginine group recieves 10 g/day arginine powder in 2 seprate 5 gram doses. Intervention 2: Citrulline group recieves 10 g/day citrulline powder in 2 seprated 5 gram doses. Interventi

Treatment - Other

Arginine group recieves 10 g/day arginine powder in 2 seprate 5 gram doses

Citrulline group recieves 10 g/day citrulline powder in 2 seprated 5 gram doses

control group will not recieves any supplement

Eligibility

Sex/Gender

All

Age

20 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: AGE:20-70 years old ;BMI:18.5-30 Exclusion criteria: hemodynamically and metabolically unstable patients; more than 3 days NPO; any condition that we can not use enteral feeding

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Death. Timepoint: 28 days follow up. Method of measurement: daily assessment.;Body mass index. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on BMI equation.;Ventilator depending. Timepoint: during hospital stay. Method of measurement: daily assessment.;Lenght of hospital stay. Timepoint: in day of release. Method of measurement: based on date of admission and release.;ALT. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;AST. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;SEVIERITY OF ILLNESS. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: APACHEII.;LDH. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;ALP. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;FBS. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;BUN. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;CREATININE. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;CHOLESTROL. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;LDL. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;HDL. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;TG. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;BILLIRUBIN TOTAL. Timepoint: day 0 and day 11	—

Measure

Time frame

Death. Timepoint: 28 days follow up. Method of measurement: daily assessment.;Body mass index. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on BMI equation.;Ventilator depending. Timepoint: during hospital stay. Method of measurement: daily assessment.;Lenght of hospital stay. Timepoint: in day of release. Method of measurement: based on date of admission and release.;ALT. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;AST. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;SEVIERITY OF ILLNESS. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: APACHEII.;LDH. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;ALP. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;FBS. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;BUN. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;CREATININE. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;CHOLESTROL. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;LDL. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;HDL. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;TG. Timepoint: day 0 and day 11 (first and last days of intervention). Method of measurement: based on labratory measurement.;BILLIRUBIN TOTAL. Timepoint: day 0 and day 11

—

Secondary

Measure	Time frame
Side effect. Timepoint: during intervention. Method of measurement: daily assessment.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahareh Barkhidarian

Mashad university of medical sciences

BARKHIB881@MUMS.AC.IR+98 51 1844 5309

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026